Thomas Villiger
Vorstandsvorsitzender bei Mepha AG
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Martin Schmid | M | 55 | 8 Jahre | |
Wolfram Carius | M | 63 | 10 Jahre | |
Richard Hummel | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Michael Hilb | M | 47 |
Sigvaris Holding AG
Sigvaris Holding AG Medical SpecialtiesHealth Technology Sigvaris Holding AG manufactures medical compression stockings. Its products include medical, well being, and sports. The firm's medical line helps in the treatment of venous disorder. The company was founded in 1864 and is headquartered in Appenzell, Switzerland. | - |
Daniel Gemperle | M | 65 |
Sigvaris Holding AG
Sigvaris Holding AG Medical SpecialtiesHealth Technology Sigvaris Holding AG manufactures medical compression stockings. Its products include medical, well being, and sports. The firm's medical line helps in the treatment of venous disorder. The company was founded in 1864 and is headquartered in Appenzell, Switzerland. | 4 Jahre |
Felix Schmidlin | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Didier Relin | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Tycho Leifels | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Peter Theiler | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Katrin Stamm | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Irène Schmutz | F | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Philippe Drechsle | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Madeleine Peter-Stampfli | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Pétur Olafsson | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Walter Saladin | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Victor Brantl | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Christa Jackson | F | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Michael Bauer | M | - |
Mepha AG
Mepha AG Pharmaceuticals: MajorHealth Technology Mepha develops and makes interesting pharmaceuticals in Switzerland, as well as offering attractive services, so that doctors and pharmacists can treat their patients both more effectively and in a more price-conscious way. This is achieved by team work and innovative spirit, examples of which are as follows. Its innovative dosage forms are more readily accepted by patients, so the patient compliance is higher, which makes for a more effective treatment. It has been involved in the fight against malaria for over 20 years, and introduced a state-of-the-art combination drug with the active substances mefloquine and artesunate (Artequin™) on the international market in 2002 for the treatment of this disease. It can offer many creative services and target-oriented two-way communication to help its clients in the treatment of their patients. Its highly motivated employees add their friendly approach to its comprehensive portfolio for the benefit of its clients. | - |
Christa Brügger | F | - | 10 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Karl W. Gschwend | M | 71 |
Swiss Federal Institute of Technology
| 9 Jahre |
René Imwinkelried | M | 67 | 8 Jahre | |
Sergio Magistri | M | - |
Swiss Federal Institute of Technology
| 8 Jahre |
Ulla Schmidt | F | 75 | - | |
Victor Waldemar Balli | M | 67 |
Swiss Federal Institute of Technology
| 5 Jahre |
Colin Bond | M | 64 | 10 Jahre | |
Reto A. Garzetti | M | 64 | - | |
Gian-Luca Bona | M | 67 |
Swiss Federal Institute of Technology
| 8 Jahre |
Beat In-Albon | M | 72 | 1 Jahre | |
Mehmet Tara | M | 66 |
Swiss Federal Institute of Technology
| 4 Jahre |
Jost Krüttli | M | 73 |
Swiss Federal Institute of Technology
| 4 Jahre |
Pierre-François Veillon | M | 74 |
Swiss Federal Institute of Technology
| 1 Jahre |
Arnoud A. Middel | M | 53 | 12 Jahre | |
Walter Kittl | M | 68 | 5 Jahre | |
Jean-Daniel Borgeaud | M | 66 |
Swiss Federal Institute of Technology
| 4 Jahre |
George P. Sagredos | M | 71 |
Swiss Federal Institute of Technology
| 1 Jahre |
Alfons Traxler | M | - |
Swiss Federal Institute of Technology
| 4 Jahre |
Periclès–Paul P. Petalas | M | 81 |
Swiss Federal Institute of Technology
| 1 Jahre |
Veli Ergin Imre | M | 66 |
Swiss Federal Institute of Technology
| 4 Jahre |
Simon Jones | M | - |
Swiss Federal Institute of Technology
| 4 Jahre |
Peter Pleus | M | - |
Swiss Federal Institute of Technology
| 3 Jahre |
Claude Flueckiger | M | - |
Swiss Federal Institute of Technology
| 3 Jahre |
Ulrich Schaumann | M | 67 |
Swiss Federal Institute of Technology
| 3 Jahre |
Laurent Vulliet | M | 66 |
Swiss Federal Institute of Technology
| 4 Jahre |
Hans Brändle | M | 63 |
Swiss Federal Institute of Technology
| 14 Jahre |
Dominique Durant des Aulnois | M | - |
Swiss Federal Institute of Technology
| 4 Jahre |
Ernesto Schümperli | M | 68 |
Swiss Federal Institute of Technology
| 4 Jahre |
Fritz Gantert | M | 66 |
Swiss Federal Institute of Technology
| 5 Jahre |
Peter Baumann | M | 68 |
Swiss Federal Institute of Technology
| 4 Jahre |
Peter Leupp | M | 72 |
Swiss Federal Institute of Technology
| 4 Jahre |
Walter Blättler | M | 75 |
Swiss Federal Institute of Technology
| 3 Jahre |
Christoph Alexander Schoeller | M | 65 |
Swiss Federal Institute of Technology
| 4 Jahre |
Armin Meyer | M | 75 |
Swiss Federal Institute of Technology
| 3 Jahre |
Bruno E. Raschle | M | - |
Swiss Federal Institute of Technology
| 4 Jahre |
Thomas Staehelin | M | 76 | 21 Jahre | |
Andreas Niklaus Koopmann-Zulliger | M | 73 |
Swiss Federal Institute of Technology
| 1 Jahre |
Jean-Pierre Obrecht | M | - |
Swiss Federal Institute of Technology
| 3 Jahre |
Bernhard Jucker | M | 70 |
Swiss Federal Institute of Technology
| 4 Jahre |
Martin Bachmann | M | 65 |
Swiss Federal Institute of Technology
| 5 Jahre |
Reto Crameri | M | - |
Swiss Federal Institute of Technology
| 3 Jahre |
Alexander Jakob Boris Zehnder | M | - |
Swiss Federal Institute of Technology
| 3 Jahre |
Jürg Spillmann | M | - |
Swiss Federal Institute of Technology
| 4 Jahre |
Gilbert Achermann | M | 60 | 5 Jahre | |
Niklaus Peter Nüesch | M | 70 |
Swiss Federal Institute of Technology
| 7 Jahre |
Romain Becker | M | 70 |
Swiss Federal Institute of Technology
| 4 Jahre |
Giovanni Müller | M | - |
Swiss Federal Institute of Technology
| 4 Jahre |
Erwin Stoller | M | 77 |
Swiss Federal Institute of Technology
| 1 Jahre |
Daniel Crausaz | M | 67 |
Swiss Federal Institute of Technology
| 4 Jahre |
Jakob Züger | M | 72 |
Swiss Federal Institute of Technology
| 1 Jahre |
Peter Gnägi | M | 70 |
Swiss Federal Institute of Technology
| 4 Jahre |
Jean-Christophe Hadorn | M | 67 |
Swiss Federal Institute of Technology
| 1 Jahre |
Caroline Geuissaz | F | - |
Swiss Federal Institute of Technology
| 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Deutschland | 43 | 60,56% |
Schweiz | 28 | 39,44% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Thomas Villiger
- Persönliches Netzwerk